Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — The co-founders of the ...

CEO Ugur Sahin said BioNTech’s 2026 priorities are to “accelerate the late-stage development of our oncology assets,” build “momentum in combination therapy” around “Pumitamig as potential ...

BioNTech continues to sharpen its strategic focus on the growing late-stage clinical pipeline spanning immunomodulator, ADC and mRNA candidates BioNTech co-founders Ugur Sahin and Özlem Türeci will ...

CEO Ugur Sahin highlighted that BioNTech maintained its leadership in the COVID vaccine market, launching a variant-adapted vaccine in partnership with Pfizer, now distributed in over 180 countries ...

The CEO of BioNTech Ugur Sahin was inoculated in early 2021 with the COVID-19 vaccine his team developed with Pfizer, a company spokesperson told Reuters, contrary to social media posts sharing an ...

BioNTech's stock fell 19% after its co-founders said they are leaving to start a new mRNA-based company Ugur Sahin and Özlem Türeci, the co-founders of BioNTech, were given the Axel Springer Award in ...

BioNTech founders to start new company by end-2026 New venture to focus on mRNA-based next-gen drugs Shares plunge 21% to their lowest since August 2024 Sahin and Tuereci plan to work on early drug ...

By Ludwig Burger FRANKFURT, March 10 (Reuters) - The two co-founders and leading executives of Germany's BioNTech will leave the COVID-19 vaccine maker by the end of 2026 to ‌start again with a new ...